Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype

Annals of Clinical and Translational Neurology

Volumn 4, Issue 1, 2017, Pages 15-25

  Cooper, Christine A ^a,b   Jain, Nimansha ^b   Gallagher, Michael D ^b   Weintraub, Daniel ^b   Xie, Sharon X ^b   Berlyand, Yosef ^b,c   Espay, Alberto J ^d   Quinn, Joseph ^e   Edwards, Karen L ^f   Montine, Thomas ^g   Van Deerlin, Vivianna M ^b   Trojanowski, John ^b   Zabetian, Cyrus P ^g   Chen Plotkin, Alice S ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; LEVODOPA;

ADULT; ARTICLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; GAIT DISORDER; GENE EXPRESSION; GENE REPLICATION; GENETIC ANALYSIS; GENETIC VARIATION; GENOTYPING TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 85015837322     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.371     Document Type: Article

References (52)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
2. Vu TC, Nutt JG, Holford NHG. Progression of motor and nonmotor features of Parkinson's disease and their response to treatment: progression of Parkinson's disease. Br J Clin Pharmacol 2012;74:267–283.
3. Liu P, Feng T, Wang Y, et al. Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis. J Zhejiang Univ Sci B 2011;12:694–703.
4. Fereshtehnejad S-M, Romenets SR, Anang JBM, et al. New clinical subtypes of parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 2015;72:863.
5. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease A base-line analysis of the DAT ATOP cohort. Neurology 1990;40:1529–1529.
6. Factor SA, Steenland NK, Higgins DS, et al. Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis. J Neurol Neurosurg Psychiatry 2011;82:564–568.
7. Ma L-Y, Chan P, Gu Z-Q, et al. Heterogeneity among patients with Parkinson's disease: cluster analysis and genetic association. J Neurol Sci 2015;351(1–2):41–45.
8. Flensborg Damholdt M, Shevlin M, Borghammer P, et al. Clinical heterogeneity in Parkinson's disease revisited: a latent profile analysis. Acta Neurol Scand 2012;125:311–318.
9. van Rooden SM, Colas F, Martínez-Martín P, et al. Clinical subtypes of Parkinson's disease. Mov Disord 2011;26:51–58.
10. Selikhova M, Williams DR, Kempster PA, et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain J Neurol 2009;132(Pt 11):2947–2957.
11. Fahn S, Elton R; Members of the UPDRS Development Committee. 1987. Unified Parkinson's Disease Rating Scale In: Fahn S, Marsden C, Caine D, Goldstein M, ed. Recent Developments in Parkinson's Disease. Florham Park, NJ, Macmillan Health Care Information.
12. Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006;21:1123–1130.
13. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001;58:1611–1615.
14. Verbaan D, Marinus J, Visser M, et al. Cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:1182–1187.
15. Burn DJ. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006;77:585–589.
16. Goldman JG, Weis H, Stebbins G, et al. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord 2012;27:1129–1136.
17. Wu Y, Guo X-Y, Wei Q-Q, et al. Non-motor symptoms and quality of life in tremor dominant vs postural instability gait disorder Parkinson's disease patients. Acta Neurol Scand 2015;5:330–337.
18. Burn DJ, Landau S, Hindle JV, et al. Parkinson's disease motor subtypes and mood. Mov Disord 2012;27:379–386.
19. Wylie SA, van den Wildenberg W, Ridderinkhof KR, et al. Differential susceptibility to motor impulsivity among functional subtypes of Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:1149–1154.
20. Lo RY, Tanner CM, Albers KB, et al. Clinical features in early Parkinson disease and survival. Arch Neurol 2009;66:1353–1358.
21. Auyeung M, Tsoi TH, Mok V, et al. Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson's disease patients. J Neurol Neurosurg Psychiatry 2012;83:607–611.
22. Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society-sponsored revision of the unified parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–2170.
23. Stebbins GT, Goetz CG, Burn DJ, et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale: PIGD and The MDS-UPDRS. Mov Disord 2013;28:668–670.
24. Nalls MA, Bras J, Hernandez DG, et al. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging 2015;36:1605.e7–1605.e12.
25. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014;46:989–993.
26. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963–974.
27. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007;129:823–837.
28. Heintzman ND, Stuart RK, Hon G, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007;39:311–318.
29. Creyghton MP, Cheng AW, Welstead GG, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci USA 2010;107:21931–21936.
30. Zhou X, Wang T. Using the Wash U Epigenome Browser to examine genome-wide sequencing data. Curr. Protoc. Bioinforma. Ed. Board Andreas Baxevanis Al 2012;Chapter 10:Unit10.10.
31. GTEx Consortium, Ardlie KG, Deluca DS, Segrè AV, et al. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 2015;348:648–660.
32. Genomes Project Consortium; Abecasis GR, Auton A, Brooks LD, et al. An integrated map of genetic variation from 1092 human genomes. Nature 2012;491:56–65.
33. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263–265.
34. Rada-Iglesias A, Bajpai R, Swigut T, et al. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 2011;470:279–283.
35. Hadjigeorgiou GM, Xiromerisiou G, Gourbali V, et al. Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset. Mov Disord 2006;21:534–539.
36. Cardo LF, Coto E, de Mena L, et al. A search for SNCA 3′ UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease. J Mol Neurosci MN 2012;47:425–430.
37. Brockmann K, Schulte C, Hauser A-K, et al. SNCA: major genetic modifier of age at onset of Parkinson's disease. Mov Disord 2013;28:1217–1221.
38. Ritz B, Rhodes SL, Bordelon Y, Bronstein J. α-Synuclein genetic variants predict faster motor symptom progression in idiopathic parkinson disease. PLoS ONE 2012;7:e36199.
39. Markopoulou K, Biernacka JM, Armasu SM, et al. Does α -synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease? Parkinsonism Relat Disord 2014;20:584–589.
40. Louis ED, Tang MX, Cote L, et al. Progression of parkinsonian signs in Parkinson disease. Arch Neurol 1999;56:334–337.
41. Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The clinically important difference on the Unified Parkinson's Disease Rating Scale. Arch Neurol 2010;67:64–70.
42. Hill-Burns EM, Wissemann WT, Hamza TH, et al. Identification of a novel Parkinson's disease locus via stratified genome-wide association study. BMC Genom 2014;15:118.
43. McCarthy JJ, Linnertz C, Saucier L, et al. The effect of SNCA 3′ region on the levels of SNCA-112 splicing variant. Neurogenetics 2011;12:59–64.
44. Mata IF, Shi M, Agarwal P, et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 2010;67:1350–1356.
45. Guella I, Evans DM, Szu-Tu C, et al. α -synuclein genetic variability: A biomarker for dementia in Parkinson disease. Ann Neurol 2016;79:991–999.
46. Ross OA, Braithwaite AT, Skipper LM, et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 2008;63:743–750.
47. Singleton AB, Farrer M, Johnson J, et al. α -Synuclein locus triplication causes Parkinson's Disease. Science 2003;302:841.
48. Fuchs J, Tichopad A, Golub Y, et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 2008;22:1327–1334.
49. Cardo LF, Coto E, de Mena L, et al. Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms. Neurosci Lett 2014;562:45–49.
50. GTEx Consortium, Lonsdale J, Thomas J, Salvatore M, et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013;45:580–585.
51. Beecham GW, Dickson DW, Scott WK, et al. PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology 2015;84:972–980.
52. Josephs KA, Matsumoto JY, Ahlskog JE. Benign tremulous parkinsonism. Arch Neurol 2006;63:354–357.